Skip to main content

Table 6 Risk of heart failure or hospitalization for heart failure among patients with type 2 diabetes receiving glucagon-like peptide-1 receptor agonists treatment

From: Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies

Comparison Number of studies (Events or cases, patients) GLP-1 agonists (events/patients) Control (events/patients) Effect Estimate (95%CI) Cardiovascular morbidities at baseline
1. Heart failure
 Randomized controlled trials
  GLP-1 agonists vs. control 20 (36, 11758) 17/7441 19/4317 Pooled OR 0.62 (0.31 to 1.22) Typically without CVD at baseline
 Cohort studies
  GLP-1 agonists vs. SU 1 (528, 13185) NR NR Adjusted HR 1.10 (0.99 to 1.22) No history of CVD or congestive heart failure at baseline
  Exenatide vs. insulin Exenatide + insulin vs. insulin 1 (2338, 39225) 49/2804
195/7870
2094/28551
2094/28551
Adjusted HR 0.34 (0.22, 0.52)
Adjusted HR 0.40 (0.32, 0.50)
With or without CVD at baseline
  Exenatide vs. basal insulin 1 (2, 882) 0/444 2/438 Unadjusted OR 0.13 (0.01 to 2.13) NR
2. Hospitalization for heart failure
 Randomized controlled trials
  Lixisenatide vs. placebo 1 (249, 6068) 122/3034 127/3034 Pooled Adjusted HR 0.96 (0.75, 1.23) Acute coronary syndrome
 Nested case–control studies
  GLP-1 agonists vs. other OADs 1 (1118, 18744)    Adjusted OR 0.67 (0.32 to 1.42) With or without CVD at baseline
  1. GLP-1 glucagon-like peptide-1, CVD cardiovascular disease, SU sulfonylurea, OR odds ratio, HR hazard ratio, NR not reported, OADs oral antidiabetic drugs